FindTrial
Sign In

The Effect of Terlipressin on Intesitnal Function in Septic Shock Patients

the Surgical Intensive Care Unit

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02306239
Enrollment
40
Registered
2014-12-03
Start date
2014-12-31
Completion date
Unknown
Last updated
2014-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock, Terlipressin

Brief summary

Terlipressin becomes a vasopressin for septic shock. But some studies found it may lead to severe intesitnal complications such as intestinal ischemia. The investigators study was designed to find the effect of terlipressin on intestinal function in septic shock patients.

Interventions

DRUGTerlipressin
DRUGNorepinephrine

Sponsors

Liu ZiMeng
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* septic shock

Exclusion criteria

* shock due to other reasons * diagnosited intesitinal ischemia

Design outcomes

Primary

MeasureTime frame
intestinal function assessed by abdominal distension, intestinal bleeding, peritonitis, plasma DAO level, enteral nutrition7 days

Countries

China

Contacts

Primary Contactliu zimeng, master
sumslzm@163.com020-87755766
Backup Contactzhang xuyu, master
sumsxyz@163.com020-87755766

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026